This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Frederick Appelbaum, A World Expert In Blood Cancers, Named Deputy Director Of Fred Hutchinson Cancer Research Center

SEATTLE, Sept. 17, 2013 /PRNewswire/ --  Frederick R. Appelbaum, M.D., a world expert in the research and treatment of blood cancers who for the past two decades has served as senior vice president and director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, has been named executive vice president and deputy director of Fred Hutch. His appointment is effective immediately.

"We are all delighted that Fred, who has essentially lived his life at the Hutch, will now devote his energies and experience to telling our story to the world outside our walls," said Lawrence Corey, M.D., president and director of Fred Hutch. "Fred's experience, together with his vast knowledge of science and the history of the Hutch, will be invaluable in developing the community relationships and programs that we and our clinical partner, the Seattle Cancer Care Alliance, need for continued growth and impact."

While he will continue to conduct research, in his new role representing the Hutch Appelbaum will lead the institution's strategic research partnerships. "Fred is already an international figure in oncology, and he will devote more time to working with the National Cancer Institute and other federal agencies," Corey said.

As deputy director Appelbaum also will focus on maintaining the fiscal health of Fred Hutch through sustained federal funding and other revenue sources, including philanthropy and technology transfer.

"The mission of Fred Hutch is to eliminate cancer as a cause of suffering and death. If we are going to be successful in that effort, we need continued resources, and helping to ensure that will be a big part of my new role," Appelbaum said.

One such example is working with the NIH and National Cancer Institute to secure continuous renewal of the Cancer Center Support Grant, which funds the infrastructure of the Fred Hutchinson/University of Washington Cancer Consortium, one of 41 NCI-designated Comprehensive Cancer Centers nationwide. Other initiatives involve the interaction of the Hutch with its partners in support of initiatives such as a joint UW/Fred Hutch program in cancer molecular diagnostics currently under development.

"My new role will allow me to focus more specifically on the implementation of these key scientific strategies and partnerships. I truly believe that these initiatives will have a profound and lasting impact on the future of Fred Hutch," he said.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs